China-based precision cancer drug and diagnostics technology developer Gene+ has raised more than RMB250m ($38m) in a series B-plus round featuring ophthalmology care provider Aier Eye Hospital Group, 36Kr reported on Tuesday.
Private equity firm Huagai Capital led the round, which also featured Shengshan Assets, the asset management firm also known as WisdoMont, as well as Sharewin Investment and Honghui Capital.
Gene+ provides genetic testing systems for early detection of cancer, as well as developing precision drug treatments. The funding will support the further development of its next-generation sequencing technology.
The company received $30m in a 2016 series A round led by genome sequencing services provider BGI Group that included Green Pine Capital Partners and Shanghai Huoshanshi Capital.
Undisclosed investors provided a further $7.4m in January 2019 before Gene+ added $28m in series B funding from BGI, IT services firm UEC, Co-Stone Asset Management, Volcanics Venture, Green Pine Capital Partners and Desun Asset nine months later.
